Europe's Health Crisis: Are 1 in 3 People Living on Borrowed Time? Discover the Shocking Truth!

As the European Union grapples with escalating health challenges, recent legislative initiatives like the Safe Hearts Plan underscore a growing momentum for comprehensive EU-level strategies. The urgency is palpable: rising mortality rates from chronic diseases, which impact millions of Europeans, and widening treatment gaps highlight an undeniable need for action.

At the recent Parliament’s Health Summit, Members of the European Parliament (MEPs), industry representatives, and health advocacy organizations convened to discuss these pressing issues. Cardiometabolic diseases—a cluster of conditions including type 2 diabetes, high blood pressure, high cholesterol, and obesity—were highlighted as particularly urgent. Eirini Agapidaki, Greece's Alternate Minister of Health, emphasized the need for a paradigm shift: “We need to move beyond campaigns, beyond advocacy,” she stated, calling for equitable secondary prevention actions across all member states. She stressed the difference between opportunistic screening and universal screening, advocating for the latter as vital for effective health outcomes.

This sentiment was echoed by MEP Peter Agius (EPP, Malta), who reiterated the necessity for a concrete approach that addresses food consumption and lifestyle habits at the EU level. He cited the 2021 Beating Cancer Plan as a successful model to emulate. “I hate a Europe that decides for us,” Agius remarked, “but we want Europe to help us decide.”

Health inequality also emerged as a central theme. Agius referred to the 2011 Cross Border Directive, which allows EU citizens to seek treatment abroad with reimbursement from their home country, as a crucial tool in tackling health disparities. He highlighted the stark differences in survival expectations for certain health conditions across member states: “We need to recognize the fact that some health conditions will kill you in a year in some Member States and where you would have five or ten years survival expectation in other Member States.”

Pawel Tokarzewski, Hungary Country Manager at Eli Lilly, noted that obesity, a catalyst for many cardiometabolic conditions, should be recognized as a disease in itself. This reflects a broader acknowledgment of how societal health challenges necessitate unified action.

On another front, neurological diseases were identified as a silent epidemic requiring urgent EU-level intervention. Affecting one in three Europeans, these conditions prompted Astrid Arnesen, President of the European Federation of Neurological Associations, to call for immediate joint action comparable to the response to COVID-19. Arnesen pointed out that stigma and unmet medical needs exacerbate misunderstandings surrounding these diseases. Olaf Weppner, Vice President of Europe Region North at AbbVie, observed that “neurological diseases are still an empty book compared to other parts of health,” complicating access to care. He advocated for a holistic approach that spans research, industry, and healthcare delivery across member states.

MEP Tomislav Sokol (EPP, Croatia), a member of the SANT committee, underscored that achieving concrete benchmarks, data, and objectives at the EU level is fundamental in combating these diseases. He called for prioritizing brain health in EU funding, emphasizing its repercussions on productivity and long-term economic benefits.

Across party lines, MEP Marta Temido (S&D, Portugal) stressed the urgent need for a comprehensive brain strategy grounded in a human-rights-based approach to treatment access. She highlighted the ongoing shortage of healthcare professionals, advocating for better planning, training, and treatment for existing workers.

The workforce issue extends beyond neurological diseases. Sokol addressed broader systemic challenges, advocating for measures to protect healthcare workers’ quality of life, including reducing excessive shifts and investing in better infrastructure. “I don’t want to be treated by a healthcare worker who hasn’t slept in 36 hours,” he stated.

Rare diseases also emerged as a significant challenge within this systemic context. Rosa Castro, Public Affairs Director at EURORDIS Rare Diseases Europe, noted progress made through initiatives like orphan drug legislation and the ERDERA partnership. However, she emphasized the vital need for a collective EU action plan to streamline efforts and improve access to care across member states. “Rare diseases are a stress test of the Commission’s capacity to bring approaches together with success,” she remarked.

Castro also highlighted the connection between rare diseases and advancements in biotechnology, suggesting that increased investment could provide the EU with a competitive advantage. Supporting this vision, Enrique Terol García, Health Counsellor of the Permanent Representation of Spain to the EU, pointed to Spain’s development of two rare disease strategies and an ongoing third strategy aimed at creating an ecosystem of connected expert centers.

Furthermore, Alessio Amadasi, Vice President of Medical Affairs – EU/International at Chiesi, emphasized the potential of utilizing available health data through the European Health Data Space, which could facilitate earlier diagnoses by identifying patterns indicating rare diseases.

Daria Julkowska, Scientific Coordinator at ERDERA, noted that public-private partnerships are crucial not only for funding but also for expertise, which could accelerate treatment discoveries—aiming for a target of a thousand new therapies for rare conditions by 2030.

The Health Summit highlighted a shared understanding that Europe’s health challenges require more than fragmented national responses. There was a consensus on the necessity of binding EU-wide strategies that translate into tangible improvements in prevention, diagnosis, and care. Whether cardiometabolic conditions receive the systematic intervention they demand or rare diseases serve as a gauge for EU coordination will hinge on the bloc’s ability to transition from consensus to actionable solutions.